CL2021003134A1 - Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos - Google Patents

Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos

Info

Publication number
CL2021003134A1
CL2021003134A1 CL2021003134A CL2021003134A CL2021003134A1 CL 2021003134 A1 CL2021003134 A1 CL 2021003134A1 CL 2021003134 A CL2021003134 A CL 2021003134A CL 2021003134 A CL2021003134 A CL 2021003134A CL 2021003134 A1 CL2021003134 A1 CL 2021003134A1
Authority
CL
Chile
Prior art keywords
compounds
isoindoline
oxo
compositions
methods
Prior art date
Application number
CL2021003134A
Other languages
English (en)
Inventor
Frans Baculi
Katherine Northcote
Matthew D Correa
Joshua Hansen
Laurie A Lebrun
Chin-Chun Lu
Gang Lu
Mark A Nagy
Sophie Peng
Sophie Perrin-Ninkovic
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2021003134A1 publication Critical patent/CL2021003134A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente compuestos de 1-oxo-isoindolin-5-carboxamida que tienen la siguiente estructura: en donde R1, R2, R3, R4 y n son como se definen en la presente, composiciones que comprenden una cantidad eficaz de un compuesto de 1-oxo-isoindolin-5-carboxamida, y métodos para tratar o prevenir trastornos.
CL2021003134A 2019-05-31 2021-11-24 Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos CL2021003134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
CL2021003134A1 true CL2021003134A1 (es) 2022-07-01

Family

ID=73551319

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003134A CL2021003134A1 (es) 2019-05-31 2021-11-24 Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos

Country Status (17)

Country Link
US (2) US11306101B2 (es)
EP (1) EP3976595A4 (es)
JP (1) JP7496838B2 (es)
KR (1) KR20220016167A (es)
CN (2) CN114957212B (es)
AR (1) AR119057A1 (es)
AU (1) AU2020282748A1 (es)
BR (1) BR112021022758A2 (es)
CA (1) CA3136753A1 (es)
CL (1) CL2021003134A1 (es)
CO (1) CO2021015624A2 (es)
IL (1) IL288278A (es)
MX (1) MX2021014350A (es)
PE (1) PE20220569A1 (es)
SG (1) SG11202112872YA (es)
TW (1) TW202110819A (es)
WO (1) WO2020243379A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136753A1 (en) 2019-05-31 2020-12-03 Frans BACULI Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
US20220387405A1 (en) * 2021-05-06 2022-12-08 Celgene Corporation Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide
KR20240019272A (ko) * 2021-06-08 2024-02-14 항저우 글루바이오 파마수티컬 코., 엘티디. 이소인돌리논 화합물 및 이의 용도
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2023244818A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2024120441A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
AU2006285144A1 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
KR20090060314A (ko) 2006-08-30 2009-06-11 셀진 코포레이션 5-치환 이소인돌린 화합물
CN101578277A (zh) * 2006-08-30 2009-11-11 细胞基因公司 5-取代的异二氢吲哚化合物
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
CA3136753A1 (en) 2019-05-31 2020-12-03 Frans BACULI Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CO2021015624A2 (es) 2022-02-28
EP3976595A4 (en) 2023-01-04
BR112021022758A2 (pt) 2022-03-22
MX2021014350A (es) 2022-02-21
CA3136753A1 (en) 2020-12-03
CN114957212B (zh) 2024-05-24
US11306101B2 (en) 2022-04-19
EP3976595A1 (en) 2022-04-06
AR119057A1 (es) 2021-11-17
AU2020282748A1 (en) 2021-12-09
CN114269729A (zh) 2022-04-01
US20200377512A1 (en) 2020-12-03
TW202110819A (zh) 2021-03-16
IL288278A (en) 2022-01-01
JP2022534979A (ja) 2022-08-04
SG11202112872YA (en) 2021-12-30
US20220213115A1 (en) 2022-07-07
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
WO2020243379A1 (en) 2020-12-03
CN114957212A (zh) 2022-08-30
JP7496838B2 (ja) 2024-06-07

Similar Documents

Publication Publication Date Title
CL2021003134A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CO2018003168A2 (es) Moduladores de la expresión de kras
CO2021007973A2 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
NI201300113A (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas.
NI202100018A (es) Moduladores de la expresión de pnpla3
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CO2022018653A2 (es) Compuestos de unión a cereblón, composiciones de estos y métodos de tratamiento con estos
CO2022000481A2 (es) Inhibidores de enzimas
CR20190471A (es) Moduladores de la expresión de pcsk9
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
NI202000085A (es) Moduladores de la expresión de apol1
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3
BR112021018266A2 (pt) Composições e métodos para tratar formas positivas de receptor andrógeno de câncer
AR117079A1 (es) Moduladores de la expresión de foxp3
EA202191657A1 (ru) Модуляторы экспрессии hsd17b13